Levels of tacrolimus after treatment for chronic hepatitis C with direct antiviral agents in solid organ transplant reci
- PDF / 676,374 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 18 Downloads / 184 Views
SHORT RESEARCH REPORT
Levels of tacrolimus after treatment for chronic hepatitis C with direct antiviral agents in solid organ transplant recipients Sara Ibáñez‑García1,2 · Eduardo Zataraín‑Nicolás1,2 · Xandra García‑González1,2 · Maria Luisa Rodríguez‑Ferrero1,2 · Juan Fernández‑Yáñez1,2 · Francisco Jesús Fernández‑Avilés Díaz1,2 · Maria Sanjurjo Sáez1,2 Received: 20 May 2020 / Accepted: 21 September 2020 © Springer Nature Switzerland AG 2020
Abstract Background and objective The main objective was to evaluate the impact of Hepatitis C Virus treatment with direct-acting antiviral agents on tacrolimus blood levels in recipients of kidney and heart allografts. Method We analysed Hepatitis C Virus infected adult patients who received tacrolimus as immunosuppressive maintenance therapy and received direct-acting antiviral agents treatment in a tertiary hospital with solid transplant multidisciplinary program in Madrid, Spain. Liver and renal function, tacrolimus dose and blood levels were analysed before and 12 weeks after the end of treatment. Results We identified 7 kidney and 2 heart transplant recipients. All patients achieved sustained virologic response at 24 weeks. At week 12 after treatment, all liver functionality tests improved significantly with no significant changes in renal function. A decrease in the tacrolimus blood level/dose ratio for every patient was observed (370.04 ± 253.93 vs. 186.44 ± 123.74 ng/mL per mg/ kg; p
Data Loading...
